Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
5
×
biotech
5
×
boston blog main
boston top stories
life sciences
national blog main
national top stories
new york blog main
new york top stories
novartis
5
×
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
deals
diagnostics
merck
pfizer
abbvie
alder biopharmaceuticals
alnylam pharmaceuticals
alzheimer's disease
cancer
cystic fibrosis
What
drug
5
×
bio
new
roundup
acquisitions
biggest
brings
ceo
company
fda
medicines
patients
acquire
advantages
agreed
albert
amgen
approval
bar
billion
bourla
build
buy
candidates
cash
cholesterol
class
company’s
compound
crispr
daniel
deal
debut
developed
dyne’s
expect
future
gamble
gets
gilead
Language
unset
unknown
Current search:
drug
×
biotech
×
novartis
×
amgen
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines